Potential and limitations in early diagnosis of ovarian cancer

Advances in Experimental Medicine and Biology

Volumn 622, Issue , 2008, Pages 3-14

  Urban, Nicole ^a   Drescher, Charles ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MORTALITY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

EID: 84934434273     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-68969-2_1     Document Type: Review

References (25)

1. Ries, L. A. G., D. Harkins, et al. (2006). SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute.
2. Petricoin, III, E. F., A. M. Ardekani, et al. (2002). "Use of proteomic patterns in serum to identify ovarian cancer." Lancet 359(9306): 572-577.
3. Mor, G. I., Visintin, et al. (2005). "Serum protein markers for early detection of ovarian cancer." Proc Natl Acad Sci USA 102(21): 7677-7682.
4. Urban, N. and C. Drescher (2006). "Current and future developments in screening for ovarian cancer." Women's Health 2(5): 733-742.
5. Bast, R. C., Jr., T. L. Klug, et al. (1984). "Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen." Am J Obstet Gynecol 149(5): 553-559.
6. Jha, P., A. Farooq, et al. (1991). "Use of serum prolactin for monitoring the therapeutic response in ovarian malignancy." Int J Gynaecol Obstet 36(1): 33-38.
7. Scholler, N., N. Fu, et al. (1999). "Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma." Proc Natl Acad Sci USA 96(20): 11531-11536.
8. Diamandis, E. P., A. Okui, et al. (2002). "Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma." Cancer Res 62(1): 295-300.
9. Kim, J. H., S. J. Skates, et al. (2002). "Osteopontin as a potential diagnostic biomarker for ovarian cancer." JAMA 287(13): 1671-1679.
10. Hellstrom, I., J. Raycraft, et al. (2003). "The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma." Cancer Res 63(13): 3695-3700.
11. Salceda, S., T. Tang, et al. (2005). "The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation." Exp Cell Res306(1): 128-141.
12. Matsuzaki, H., H. Kobayashi, et al. (2005). "Plasma bikunin as a favorable prognostic factor in ovarian cancer." J Clin Oncol 23(7): 1463-1472.
13. Jacobs, I. J., S. J. Skates, et al. (1999). "Screening for ovarian cancer: a pilot randomized controlled trial." Lancet 353(9160): 1207-1210.
14. Urban, N., C. Drescher, et al. (1997). "Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening." Contr Clin Trials 18(3): 251-270.
15. Skates, S. J., U. Menon, et al. (2003). "Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women." J Clin Oncol 21(90100): 206s-210s.
16. McIntosh, M. W. and N. Urban (2003). "A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker." Biostatistics 4(1): 27-40.
17. Schummer, M., W. V. Ng, et al. (1999). "Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas." Gene238(2): 375-385.
18. Drapkin, R., H. H. von Horsten, et al. (2005). "Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas." Cancer Res 65(6): 2162-2169.
19. Israeli, O., A. Goldring-Aviram, et al. (2005). "In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer." Cancer Genet Cytogenet 160(1): 35-42.
20. McIntosh, M., C. Drescher, et al. (2004). "Mesothelin/MPF antigen(s) as a diagnostic and screening marker for ovarian carcinoma when used alone or combined with CA-125." Gynecol Oncol 95: 9-15.
21. McIntosh, M. W. and M. S. Pepe (2002). "Combining several screening tests: optimality of the risk score." Biometrics 58(3): 657-664.
22. McIntosh, M. W., N. Urban, et al. (2002). "Generating longitudinal screening algorithms using novel biomarkers for disease." Cancer Epidemiol Biomarkers Prev 11(2): 159-166.
23. Pepe, M. S., R. Etzioni, et al. (2001). "Phases of biomarker development for early detection of cancer." J Natl Cancer Inst 93(14): 1054-1061.
24. Scholler, N., M. Crawford, et al. (2006). "Bead-based ELISA for validation of ovarian cancer early detection markers." Clin Cancer Res 12(7): 2117-2124.
25. 2006). Women's Health Initiative Scientific Resources Website, available at: www.whiscience. org.